Astrazeneca Pharma India Ltd vs Cian Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8488 as of 15 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Cian Healthcare Ltd changed from 562.5 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Cian Healthcare Ltd changed from ₹ 26.28 crore on March 2021 to ₹ 8.62 crore on March 2025 . This represents a CAGR of -19.98% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Cian Healthcare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Cian Healthcare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Cian Healthcare Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Cian Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Cian Healthcare Ltd

Cian Healthcare Limited was originally incorporated as a Private Limited Company with the name of 'Cian Healthcare Private Limited' on January 07, 2003.
Subsequently, the Company was converted into a Public Limited Company and the name of the Company was changed to 'Cian Healthcare Limited' pursuant to a fresh Certificate of Incorporation granted by the Registrar of Companies, Pune dated November 30, 2018. The Company is a certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products.
The Company complies with the standard manufacturing practices as laid down by the World Health Organization and is also certified by the Food and Drug Control Administration. The Company started manufacturing unit at Roorkee in Uttarakhand in 2013.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Cian Healthcare Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Cian Healthcare Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,221 Cr while Market cap of Cian Healthcare Ltd is 20 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Cian Healthcare Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Cian Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Cian Healthcare Ltd?

As of May 17, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8488.45. On the other hand, Cian Healthcare Ltd stock price is INR ₹8.26.

How do dividend payouts of Astrazeneca Pharma India Ltd and Cian Healthcare Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Cian Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.